Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19: Graphical Abstract

Vinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1 that increase

cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN have anti-inflammatory and

antioxidant effects with suppression release of pro-inflammatory cytokines. Moreover, VPN mitigates

oxidative stress (OS) and inflammatory reactions through inhibition of mitogen-activated protein kinase

(MAPK) signaling pathway. Therefore, VPN may decrease hyper-inflammation-induced acute lung injury in

COVID-19 through modulation of NF-κB pathway. Taken together, VPN has pulmonary and extrapulmonary

protective effects against COVID-19 through mitigation of OS and hyperinflammation. In

conclusion, VPN has noteworthy anti-inflammatory and anti-oxidant effects through inhibition of NF-

κB/MAPK signaling pathway so, it may reduce SARS-CoV-2-induced hyper inflammatory and OS.